Navigation Links
2nd ESMO symposium on soft tissue carcinomas and GIST
Date:5/12/2008

Experts in treating a rare group of cancers that affect tissues such as muscle, fat, nerves and the gastrointestinal wall are meeting in Milan, Italy on 13-14 May to discuss the latest information on how these diseases develop and potential new avenues for therapy.

The 2nd Symposium on Sarcoma and GIST (Gastrointestinal Stromal Tumors) organized by the European Society for Medical Oncology (ESMO), will include sessions on the genetics of sarcomas, on understanding how drug resistance develops and possibilities for new treatment options.

There will be a particular focus on how scientists and clinicians can work together to develop new treatments, including molecular targeted therapies. The theme of the meeting is 'Insights at the crossroads of molecular biology, pathology and clinic.'

"Sarcomas are relatively rare, but they are serving as a model for the way new molecular targeted therapies are being introduced into clinical practice," said co-chair of the event Dr. Paolo G. Casali, Head of the Sarcoma Medical Treatment Unit at the Milan Istituto Nazionale Tumori and Chair of the ESMO Sarcoma Working Group. "This challenges our ability to combine information from as diverse areas as biology, pathology and the clinic to achieve better results for patients."

"The molecular and pathological bases represent extremely valuable diagnostic and prognostic information for the proper treatment of this disease, although the way we can exploit all these data in the clinic is still to be defined properly," said co-chair Dr. Paolo Dei Tos, Director of the Pathology Unit of the Regional Hospital of Treviso, Italy.

Sarcomas are cancers of the connective or supportive tissues, such as muscles, tendons, ligaments, nerves, fat and blood vessels, therefore they can arise everywhere in the body, although they are rare. Sarcomas are also different to the much more frequent carcinomas of the breast, colon, lung, and others.

Around
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
41-919-731-907
European Society for Medical Oncology
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
2. Success of Shape-Up Somerville Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston
3. NARSAD - Worlds Leading Mental Health Research Charity - Presents 19th Annual New York Mental Health Symposium, Oct. 19th & 20th
4. XShares Supports Parkinsons Disease Foundation 50th Anniversary Educational Symposium
5. Poll Shows Voters Want Long Term Care Included in Presidential Candidates Healthcare Proposals, Released at 2007 National Long Term Care Symposium
6. Cosmetic Bootcamp Solidifies Lead as Investor Symposium for Aesthetic Medicine
7. UCLA, Tokyo University nanobiotechnology symposium at UCLA to highlight advances in nanomedicine
8. AMIAs 31st Annual Symposium Opens in Chicago, IL
9. Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation
10. Aesthetic Extender Symposium, LLC Announces its Inaugural Event
11. New Taxotere(R) (docetaxel) Injection Concentrate Data to be Presented at the 30th Annual San Antonio Breast Cancer Symposium (SABCS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2010)... N.Y. -- Hockey fans likely would assume that body-checking ... causes the most injuries in youth ice hockey. But ... study, the largest and most comprehensive analysis to date ... overall injuries were caused by accidentally hitting the boards ... by a puck. , Only 34 percent of the ...
(Date:7/29/2010)... more than a thousand genes known as large intergenic ... to understanding the function and organization of the genome. ... with the finding that dozens of these lincRNAs are ... cancer), suggesting that this class of genes plays a ... researchers identify one lincRNA in particular (lincRNA-p21), and demonstrate ...
(Date:7/29/2010)... a family history of male breast cancer perceive themselves to ... patients with a family history of female breast cancer; however ... likely to know about or seek genetic testing than those ... a study led by researchers at the University of Louisville,s ... rare and accounts for only about one percent of all ...
(Date:7/29/2010)... game, developed at the University of Stavanger (UiS), is set ... , If you mention the words "drug calculationss" to a ... in return. Not only is it a difficult subject, the ... mistake in the examination leads to fail, which again bars ... medication can be fatal., At UiS the students have three ...
(Date:7/29/2010)... in Spanish . , Mushrooms are among ... in keeping the immune system healthy. Now, Agricultural Research ... study showing that white button mushrooms enhanced the activity ... In the United States, white button mushrooms represent 90 ... was conducted at the Jean Mayer USDA Human Nutrition ...
Breaking Medicine News(10 mins):Health News:Most youth hockey injuries caused by accidents, not checking, UB study shows 2Health News:'Linc-ing' a noncoding RNA to a central cellular pathway 2Health News:Male breast cancer in family leads to high perception of risk, low likelihood of genetic counseling 2Health News:Male breast cancer in family leads to high perception of risk, low likelihood of genetic counseling 3Health News:Playing with pills 2
... (Nasdaq: WHRT ) World Heart ... Investigational Device Exemption ("IDE") application to the US Food ... pivotal Bridge-to-Transplant ("BTT") study of the Levacor(TM) Ventricular Assist ... information, including design and in vitro and ...
... affected women,s ability to plan and prepare for expensive long-term ... new survey released today by America,s Health Insurance Plans (AHIP). ... found that 60 percent of women say the economy has ... "Women have been particularly hard hit by the ...
... hear it everywhere: "What is your carbon footprint?" But ... can you reduce yours? It isn,t all that complicated, ... to bring it down.Listen to this report from Siemens (NYSE: ... access video, audio, text, graphics and photos for free and ...
... prolongs lives of key vision cells in mice , , ... mice have identified a protein that appears to prolong ... diseased eyes. , The discovery could one day lead ... predisposed to develop retinal disease, the scientists said. , ...
... Yet another reason to use a treadmill desk to ... ... January 8, 2009 -- Yet another alarm bell has been set ... and the corresponding relation to disease. The National Cancer Institute completed ...
... N.C., Jan. 8 Many electronic health record,systems are ... when a child goes to his,or her primary care ... physician,s,office -- the fields in the child,s electronic health ... fields are not appropriate,for newborns; growth tracking and immunization ...
Other Medicine News:Health News:WorldHeart Submits IDE Application for a Pivotal Bridge-to-Transplant Study of the Levacor(TM) VAD 2Health News:Economic Downturn Impacting Women's Ability to Plan for Long-Term Care Costs, New Survey Finds 2Health News:Economic Downturn Impacting Women's Ability to Plan for Long-Term Care Costs, New Survey Finds 3Health News:Protein Might One Day Prevent Blindness 2Health News:Protein Might One Day Prevent Blindness 3Health News:Treadmill Desks Combat Obesity Linked to Higher Rates of Ovarian Cancer 2Health News:Treadmill Desks Combat Obesity Linked to Higher Rates of Ovarian Cancer 3Health News:Alliance for Pediatric Quality Supports New ANSI-Approved Standard for Child Health Passed by HL7 2
(Date:7/29/2010)... Asahi Kasei Medical Co., Ltd. is pleased ... of BioOptimal™ MF-SL, its new range of microfilters ... culture clarification applications, BioOptimal™ MF-SL filters enable biopharmaceutical manufacturers ... harvest step. , ... Developed using Asahi Kasei,s ...
(Date:7/29/2010)... Inc. (Nasdaq: VRML ), a molecular diagnostics company, will host a ... of Q2 financial results on Monday, August 16, 2010 . , ... Conference Call Information ... To access the live ... States and Canada or +1 212 231 2901 internationally. ...
(Date:7/29/2010)... PITTSBURGH , July 29 With diabetes affecting the ... Ohio , Giant Eagle®, Inc. has announced that it will begin ... at no cost to medical prescription holders. , ... (Logo:   http://photos.prnewswire.com/prnh/20100729/NE42933LOGO ) , ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20100729/NE42933LOGO ) , ...
Breaking Medicine Technology:Launch of BioOptimal™ MF-SL Microfilters for Bioprocessing 2Vermillion to Host Conference Call and Web Cast to Present Company Update and Review Financial Results for the Second Quarter 2010 2Vermillion to Host Conference Call and Web Cast to Present Company Update and Review Financial Results for the Second Quarter 2010 3Giant Eagle® Expands Free Prescription Program To Include Free Diabetes Medicines in Western Pennsylvania 2Giant Eagle® Expands Free Prescription Program To Include Free Diabetes Medicines in Western Pennsylvania 3Giant Eagle® Expands Free Prescription Program To Include Free Diabetes Medicines in Western Pennsylvania 4Giant Eagle® Expands Free Prescription Program To Include Free Diabetes Medicines in Western Pennsylvania 5X Chem and Roche Enter Into Drug Discovery Collaboration and License Agreement 16816 1X Chem and Roche Enter Into Drug Discovery Collaboration and License Agreement 16816 2Watson Launches Generic Exelon AE 9552 1Watson Launches Generic Exelon AE 9552 2Watson Launches Generic Exelon AE 9552 3Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone related Assets 9547 1Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone related Assets 9547 2Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone related Assets 9547 3Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone related Assets 9547 4
... Science Corporation,announced today that enrollment has completed in ... designed to enhance memory. The,IMPACT ("Improvement in Memory ... more than five hundred adults aged 65+,seeking to ... Principal Investigators for the IMPACT trial are ...
... of Phase II Study in Previous Nonresponders ... Schering-Plough,Corporation (NYSE: SGP ) today ... for boceprevir, its investigational oral hepatitis C,protease ... II study in,treatment-naive (previously untreated) hepatitis C ...
Other Medicine Technology:Study Demonstrates Mindful Approach to Aging 2Study Demonstrates Mindful Approach to Aging 3Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 2Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 3Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 4Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 5Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 6Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 7Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 8Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 9
... The Apollo Knee System has been ... through range of motion of any fixed ... area and low contact stress under loading ... contributes to long-term effectiveness. The universal symmetrical ...
The Performance Knee System is a wide and easy to use system that offers enough options to cover any indication for primary and revision knee surgery, and all this with extensive intraoperative flexi...
... component is intended for patients who ... ligament stability, yet require augmentation and/or ... stock. The NexGen CRA femoral component ... surface. This device is for cemented ...
The Duracon system provides superb articular conformity throughout the range of motion, reducing contact stresses generally associated with wear....
Medicine Products: